ColdZyme Distribution Deal for Iraq and Jordan
Sweden's Enzymatica AB has partnered with MedonyX for the exclusive distribution of its ColdZyme mouth spray in Iraq and Jordan. This long-term agreement aims to expand the product's market reach across key Middle Eastern healthcare sectors.
Enzymatica AB has successfully secured a long-term exclusive distribution agreement with MedonyX to bring its flagship ColdZyme mouth spray to Iraq and Jordan. MedonyX is backed by MMDS, a prominent Jordanian healthcare and market-access firm with deep regional expertise. The partnership covers the comprehensive registration, marketing, sales, and distribution processes necessary for a successful regional rollout. Both companies anticipate a strong market entry as consumer demand for preventative healthcare solutions remains robust in the Middle East. This strategic expansion represents a milestone for Enzymatica as it seeks to scale its international footprint beyond traditional European markets. Financial terms of the agreement were not disclosed, but initial product launches are already slated for both territories.
إخلاء مسؤولية تحليل الذكاء الاصطناعي
يُنشأ تحليل التأثير على الأصول بواسطة الذكاء الاصطناعي ولأغراض معلوماتية فقط. ولا يُعد نصيحة مالية. أجرِ بحثك الخاص دائمًا قبل اتخاذ قرارات الاستثمار.
النقاش